GRIDAI TECHNOLOGIES CORP (GRDX) Stock Price & Overview
NASDAQ:GRDX • US33749P5070
Current stock price
The current stock price of GRDX is 2.89 USD. Today GRDX is up by 18.44%. In the past month the price increased by 38.28%.
GRDX Key Statistics
- Market Cap
- 9.71M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -10.09
- Dividend Yield
- N/A
GRDX Stock Performance
GRDX Stock Chart
GRDX Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to GRDX.
GRDX Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to GRDX. GRDX has a bad profitability rating. Also its financial health evaluation is rather negative.
GRDX Earnings
GRDX Forecast & Estimates
GRDX Groups
Sector & Classification
GRDX Financial Highlights
Over the last trailing twelve months GRDX reported a non-GAAP Earnings per Share(EPS) of -10.09. The EPS increased by 53.59% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.81% | ||
| ROE | -18.98% | ||
| Debt/Equity | 0.01 |
GRDX Ownership
GRDX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.05 | 368.574B | ||
| AMGN | AMGEN INC | 15.56 | 191.752B | ||
| GILD | GILEAD SCIENCES INC | 15.57 | 170.842B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.65 | 112.224B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.01 | 79.35B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.37 | 41.318B | ||
| INSM | INSMED INC | N/A | 31.186B | ||
| NTRA | NATERA INC | N/A | 29.537B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.454B | ||
| BIIB | BIOGEN INC | 11 | 26.028B | ||
| UTHR | UNITED THERAPEUTICS CORP | 20.13 | 25.789B | ||
| MRNA | MODERNA INC | N/A | 21.305B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.501B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About GRDX
Company Profile
GridAI Technologies Corp. is a clinical stage biopharmaceutical company, which engages in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal diseases. The company is headquartered in Boca Raton, Florida and currently employs 2 full-time employees. The company went IPO on 2016-10-11. The company applies real-time AI scheduling and optimization to orchestrate devices, fleets, and grid-scale assets. The firm also focuses on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The firm's programs address significant unmet needs in GI health and comprise development of Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
Company Info
IPO: 2016-10-11
GRIDAI TECHNOLOGIES CORP
777 Yamato Road, Suite 502
Boca Raton FLORIDA US
Employees: 2
Phone: 18004831140
GRIDAI TECHNOLOGIES CORP / GRDX FAQ
What does GRDX do?
GridAI Technologies Corp. is a clinical stage biopharmaceutical company, which engages in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal diseases. The company is headquartered in Boca Raton, Florida and currently employs 2 full-time employees. The company went IPO on 2016-10-11. The company applies real-time AI scheduling and optimization to orchestrate devices, fleets, and grid-scale assets. The firm also focuses on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The firm's programs address significant unmet needs in GI health and comprise development of Adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
What is the stock price of GRIDAI TECHNOLOGIES CORP today?
The current stock price of GRDX is 2.89 USD. The price increased by 18.44% in the last trading session.
What is the dividend status of GRIDAI TECHNOLOGIES CORP?
GRDX does not pay a dividend.
How is the ChartMill rating for GRIDAI TECHNOLOGIES CORP?
GRDX has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Is GRIDAI TECHNOLOGIES CORP (GRDX) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on GRDX.
How many employees does GRIDAI TECHNOLOGIES CORP have?
GRIDAI TECHNOLOGIES CORP (GRDX) currently has 2 employees.
What is the market capitalization of GRDX stock?
GRIDAI TECHNOLOGIES CORP (GRDX) has a market capitalization of 9.71M USD. This makes GRDX a Nano Cap stock.